PharmaCyte Biotech, Inc.

Overview

Compare with another stock.

• TickerPMCB on Nasdaq¹
• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersLas Vegas, Nevada¹
• Incorporated inNV³
• Business address3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nv 89169³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Conduct a stability study on our final formulated product candidate as well as the cells from our Master Cell Bank (“MCB”);⁵ From its latest annual report

Corporate structure

PharmaCyte Biotech, Inc. sits at the top of its group. 6 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

What it owns

What PharmaCyte Biotech, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Intangibles and goodwill

Properties, in its own words

Our principal office is located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 and we lease this space on a month-to-month arrangement. This space consists of approximately 100 square feet of office space plus the use of certain shared facilities, such as a lobby, conference rooms, a kitchen and open workspaces. We believe this space will be adequate for our operations for the foreseeable future.

Item 2 of the 10-K filed Jul 29, 2026.⁵

Leadership

Who has led PharmaCyte Biotech, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerKenneth Waggoner Aug 31, 2021 to Aug 31, 2021¹⁵
• ChairKenneth Waggoner Aug 31, 2021 to Aug 31, 2021¹⁵
• Chief financial officerCarlos Trujillo Sep 3, 2021 to Nov 22, 2023¹⁶
• Chief financial officerMarylew Barnes Mar 30, 2009 to Mar 30, 2009¹⁷

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorJoshua N. Silverman named Sep 4, 2025²⁸
• DirectorRobert M. Weinstein named Sep 4, 2025²⁸
• DirectorWalker R. Wayne named Sep 4, 2025²⁸

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• PharmaCyte Biotech Australia Pty. Ltd. Australia⁴
• PharmaCyte Biotech Europe Limited Ireland⁴
• Viridis Biotech, Inc. Nevada, USA⁴

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• NUVILEX, INC.Mar 26, 2009 to Jan 9, 2015³
• EFOODSAFETY COM INCAug 20, 2001 to Mar 17, 2009³

Timeline

1. Apr 2, 20268-K Executive or director change; Shareholder vote²⁹
2. Dec 5, 20258-K Listing notice or transfer³⁰
3. Nov 18, 20258-K Financial statements and exhibits³¹
4. Oct 31, 20258-K Executive or director change; Shareholder vote³²
5. Sep 5, 20258-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure³³
6. Aug 18, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure³⁴
7. Apr 24, 20258-K Shareholder vote³⁵
8. Feb 26, 20258-K Change of auditor³⁶
9. May 23, 20248-K Entered a material agreement; Completed an acquisition or sale; Other events³⁷
10. May 1, 20248-K Shareholder vote³⁸
11. Nov 24, 20238-K Executive or director change³⁹
12. Nov 16, 20238-K Entered a material agreement; Other events⁴⁰
13. Aug 31, 2021New chief executive Kenneth Waggoner becomes CEO¹⁵

Calendar

When it reported results

1. Jul 11, 2022Reported quarterly or annual results⁴¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

166 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 35 major events, 35 insider forms, 20 large holders, 1 private raises, 55 other. The latest 20:

1. Sep 14, 202610-Q FORM 10-Q FOR JUL 2026 EDGAR
2. Jul 29, 202610-K FORM 10-K FOR APRIL 2026 EDGAR
3. Jul 17, 20264/A EDGAR
4. Jul 17, 20264/A EDGAR
5. Jul 17, 20264/A EDGAR
6. Jul 17, 20264/A EDGAR
7. Apr 2, 20264 EDGAR
8. Apr 2, 20264 EDGAR
9. Apr 2, 20264 EDGAR
10. Apr 2, 20264 EDGAR
11. Apr 2, 20268-K EDGAR
12. Mar 17, 202610-Q FORM 10-Q FOR JAN 2026 EDGAR
13. Mar 9, 2026ARS ANNUAL REPORT EDGAR
14. Mar 9, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
15. Feb 27, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
16. Feb 13, 2026SCHEDULE 13G/A EDGAR
17. Jan 7, 20264 EDGAR
18. Jan 7, 20264 EDGAR
19. Dec 18, 202510-Q FORM 10-Q FOR OCT 2025 EDGAR
20. Dec 15, 2025NT 10-Q EXTENSION EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• INTRACOASTAL CAPITAL, LLCSCHEDULE 13G/A, 7 filings Feb 11, 2022 to Feb 13, 2026⁴²
• Ayrton Capital LLCSCHEDULE 13G/A, 3 filings May 19, 2023 to Feb 13, 2025⁴³
• Iroquois Capital Management, LLCSC 13D/A, 6 filings Nov 4, 2021 to Jun 16, 2023⁴⁴
• Shay Capital LLCSC 13G/A, 2 filings Oct 20, 2022 to Feb 14, 2023⁴⁵
• SABBY MANAGEMENT, LLCSC 13G/A, 2 filings Jan 4, 2022 to Jan 10, 2023⁴⁶

Stakes it holds

PharmaCyte Biotech, Inc. has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

• FEMASYS INCSCHEDULE 13G Nov 22, 2023 to Mar 18, 2026⁴⁷
• Q/C TECHNOLOGIES, INC.SCHEDULE 13D/A May 30, 2024 to Nov 18, 2025⁴⁸

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Aug 17, 2025Raised $7 million in a private offering of equity Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 27. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How PharmaCyte Biotech, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARPharmaCyte Biotech, Inc.¹
• CIK0001157075
• Employer ID (EIN)62-1772151⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company⁵
• Incorporated inNevada⁵
• Fiscal year endsApril 30¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169¹
• Phone(917) 595.2850¹
• Shares outstanding10,735,649 as of Sep 11, 2026¹⁴
• Public float$6.3M as of Oct 31, 2025⁵
• AuditorCBIZ CPAs P.C, Morristown, New Jersey PCAOB ID 199; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceAug 20, 2001¹
• Filings471 in all: 8-K (103), 10-Q (56), UPLOAD (29), CORRESP (26), 4 (25), 3 (19), 10-K (18), 10QSB (16)¹
  All 50 form types

  NT 10-K (15), NT 10-Q (14), 10-Q/A (11), 8-K/A (9), 10-K/A (7), DEF 14A (7), DEFA14A (7), SC 13G/A (7), 10KSB (6), 424B5 (6), EFFECT (6), S-3 (6), SC 13D/A (6), 10QSB/A (5), PRE 14A (5), SC 13G (5), 4/A (4), D (4), DFAN14A (4), S-3/A (4), SB-2/A (4), SC 13D (4), SCHEDULE 13G/A (4), 424B3 (3), ARS (3), S-8 (3), S-8 POS (3), CT ORDER (2), SB-2 (2), 10KSB/A (1), 424B2 (1), 425 (1), 8-A12B (1), CERT (1), NTN 10K (1), NTN 10Q (1), PREC14A (1), S-3MEF (1), SC TO-I (1), SC TO-I/A (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Jul 29, 2026
  Quarterly report (10-Q) Sep 14, 2026
  Proxy statement (DEF 14A) Mar 9, 2026
  Latest 8-K (8-K) Apr 2, 2026

Securities registered for trading

From the cover page of the 10-K filed Jul 29, 2026 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks PharmaCyte Biotech, Inc. names in Item 1A of its 10-K filed Jul 29, 2026: 73 risks under these headings, as written.⁵

• In addition, you should carefully consider these risks when you read “forward-looking” statements elsewhere in this Report. These are statements that relate to our expectations for future events and time periods. Generally, the words “anticipate,” “expect,” “intend,” and similar expressions identify forward-looking statements. Forward-looking statements involve risks and uncertainties, and future events and circumstances could differ significantly from those anticipated in the forward-looking statements.
• Forward-Looking Statements and Associated Risks
• Risks Related to Our Financial Position, FDA Clinical Hold, Need for Additional Capital and Overall Business
• We are a biotechnology company with limited resources, a limited operating history, and no products approved for clinical trials or commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.
• As a result of the clinical hold that has been placed on our IND by the FDA, it has taken and may continue to take considerable time and expense to respond to the FDA and no assurance can be given that the FDA will remove the clinical hold in which case our business and prospects will likely suffer material adverse consequences.
• U.S. government shutdowns, reductions in FDA staffing and funding, or other disruptions to FDA operations could further delay the lifting of the clinical hold on our IND and materially harm our business.
• We contract with Austrianova for the manufacture of our product candidates for preclinical studies and clinical trials, if allowed to proceed, and expect to continue to do so for commercialization. This reliance on Austrianova increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
• If we are unable to successfully raise additional capital, our future clinical trials and product development could be limited, and our long-term viability may be threatened.
• Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product candidates. We may expend our limited resources on programs that do not yield a successful product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• We currently have no commercial revenue and may never become profitable.
• We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
• Our future revenues are unpredictable which causes potential fluctuations in operating results.

Legal proceedings

From time to time, we are subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, we do not believe that the outcome of any potential claims will have a material adverse effect on our financial condition or operating results.

On May 16, 2025, we entered into a settlement and release agreement (“Settlement Agreement”) with H.C. Wainwright & Co., LLC relating to a complaint filed on December 4, 2023, alleging a breach of contract. The Settlement Agreement resolved fully all differences, disputes or claims without admitting any liability, fault or wrongdoing on the part of all parties. The Settlement Agreement required us to pay $1.55 million, comprised of an initial payment of $1.25 million and twelve equal payments of $25,000 beginning on the one-month anniversary of the initial payment. On May 16, 2025, we also issued warrants “(First Warrant Issuance”) to purchase 343,183 shares of our common stock with an exercise price of $4.00 per share with a term of five years from the issuance date. On July 29, 2025, we issued additional warrants (“Additional Warrants”) to purchase 313,067 shares of our common stock with an exercise price of $4.00 per share with a term of five years from the issuance date. The exercise price of the First Warrant Issuance and the Additional Warrants were repriced at $0.9516 per share.

To our knowledge, there are no other material legal proceedings pending against us or any material litigation against any of our officers or directors in their capacity as such, and no such litigation is contemplated by any governmental authorities.

The opening of Item 3, Legal Proceedings.⁵